Nautilus Biotechnology raises $76m in series B funding to be first to quantify human proteome

This article was originally published here

Nautilus’ total funding now exceeds $100 million. The Nautilus platform will deliver single-molecule sensitivity more quickly, more completely, and less expensively than is possible with existing technologies. This

The post Nautilus Biotechnology raises $76m in series B funding to be first to quantify human proteome appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply